Search
FORGEN I LI3 Sicherheitsaspekte bei der Entwicklung rekombinanter Yersinia enterocolitica-Stämme als neue Lebendvakzine
FORGEN I LI3 Sicherheitsaspekte bei der Entwicklung rekombinanter Yersinia enterocolitica-Stämme als neue Lebendvakzine
FORGEN I LI2 Entwicklung neuer bakterieller Lebendimpfstoffe: Analysen zur protektiven Effizienz und zum Umweltmonitoring
FORGEN I LI2 Entwicklung neuer bakterieller Lebendimpfstoffe: Analysen zur protektiven Effizienz und zum Umweltmonitoring http://www.uni-wuerzburg.de/infektionsbiologie
FORGEN I LI1 Entwicklung neuer potentieller Lebendvakzine auf der Basis attenuierter Salmonella- und Listeria-Stämme und deren Sicherheitsaspekte
FORGEN I LI1 Entwicklung neuer potentieller Lebendvakzine auf der Basis attenuierter Salmonella- und Listeria-Stämme und deren Sicherheitsaspekte
FORGEN II IS4 Experimental infection with Leishmania parasites: induction of protective immunity using dendritic cells
FORGEN II IS4 Experimental infection with Leishmania parasites: induction of protective immunity using dendritic cells Aim of the Project:The outcome of infections with Leishmania as well as other…
FORGEN II IS3 Develpment and production of recombinant live vaccines based on a new Escherichia coli carrier system
FORGEN II IS3 Develpment and production of recombinant live vaccines based on a new Escherichia coli carrier system Aim of the Project:Development of new live vaccines consisting of the benevolent…
FORGEN II IS2 Safety and efficiency of recombinant bacterial live vaccines in immuno competent and immuno deficient mice.
FORGEN II IS2 Safety and efficiency of recombinant bacterial live vaccines in immuno competent and immuno deficient mice. The progress in molecular biology of pathogenic bacteria and advances in…
FORGEN II IS1 Development of newly designed recombinant live attenuated bacterial vaccine strains. Presentation of heterologous antigens by the plasmid-encoded type III secretion - translocation system of Yersinia enterocolitica
FORGEN II IS1 Development of newly designed recombinant live attenuated bacterial vaccine strains. Presentation of heterologous antigens by the plasmid-encoded type III secretion - translocation…
FORGEN
RESEARCH NETWORK FOR FUNDAMENTAL GENETIC TECHNOLOGY
I4 - Replicon-Technology for Assessment and Production of Adenoviruses with a High Security Profile
I4 - Replicon-Technology for Assessment and Production of Adenoviruses with a High Security Profile Based on a newly developed replicon vector system for the complementation of herpesviruses, a…
I3 - Development of Immunological Assays for Immunomonitoring in the Context of a Viral Vaccination Platform
I3 - Development of Immunological Assays for Immunomonitoring in the Context of a Viral Vaccination Platform The company AmVac Research GmbH provides a vector platformbased on a replication…